#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Intracranial Activity of Lorlatinib in Patients with Metastatic ALK-Positive NSCLC

Lorlatinib is a potent third-generation anaplastic lymphoma kinase (ALK) inhibitor with significant antitumor activity against non-small cell lung cancer (NSCLC). According to the results of an international clinical study published in the Annals of Oncology, it shows very good efficacy in treating intracranial metastases in patients who experienced disease progression during therapy with second-generation ALK inhibitors.
Source: Genetic Profile and Treatment of NSCLC 23. 7. 2021

News Thromboprophylaxis as a Common Part of Care for At-Risk Patients Requiring Hospitalization: Yes or No?

The proportion of patients requiring hospitalization who are at high risk of developing thromboembolic disease is relatively high. However, not all of these patients have this risk identified and thromboprophylaxis initiated.
Source: Thromboprophylaxis 28. 5. 2021

News Thromboprophylaxis in Generalized Pancreatic Cancer

Pancreatic adenocarcinoma is one of the tumors with the highest risk of developing thromboembolic disease (TED). Although anticoagulant treatment reduces the risk of TED, its positive effect on the overall survival of patients has not yet been proven.
Source: Thromboprophylaxis 28. 5. 2021

News Position of the Aclidinium-Bromide/Formoterol-Fumarate Combination in COPD Treatment According to Current Recommendations

Dual bronchodilator therapy, which combines long-acting muscarinic antagonists (LAMA) and long-acting β-agonists (LABA), has become an integral part of the treatment for chronic obstructive pulmonary disease (COPD). Growing evidence of the efficacy and safety of the fixed combination of aclidinium-bromide/formoterol-fumarate demonstrates that this treatment meets patient needs and the current GOLD recommendations from 2019.
Source: Treatment of Asthma and COPD 3. 6. 2021

News Current Results of Brigatinib in the Treatment of Lung Cancer

The results of the primary analysis showed a significant extension of PFS in patients with non-small cell lung cancer (NSCLC) treated with brigatinib compared to crizotinib. The recently published secondary analysis confirms these results.
Source: Non-Small Cell Lung Cancer 4. 6. 2021

News Importance of Home Parenteral Therapy: ESPEN Recommendations from 2020

Home parenteral therapy currently plays a crucial role in the treatment and prevention of malnutrition in specific patient groups. The European Society for Clinical Nutrition and Metabolism (ESPEN) published updated guidelines for home parenteral therapy in 2020, based on current evidence and expert recommendations.
Source: Parenteral Nutrition 7. 6. 2021

News Vitamins in Prevention and Treatment of COVID-19

Vitamin supplementation is an important part of therapy for various diseases, and it seems that they also play a significant role in the case of COVID-19. What kind of role? It's certainly not a panacea, but it's not something to be underestimated.
Source: Parenteral Nutrition 7. 6. 2021

News Does Peritoneal Dialysis Have Its Place Even in Acute Cases?

In patients who urgently need to replace kidney function, hemodialysis traditionally played the role of the gold standard. Can peritoneal dialysis fully replace it?
Source: Chronic Kidney Disease 8. 6. 2021

News Safety of Urgent Initiation of Peritoneal Dialysis

In case of urgent need for kidney function replacement, hemodialysis (HD) with a temporary venous catheter has long been the standard solution. However, it has several disadvantages such as increased mortality or the risk of bacteremia and central venous stenosis. Additionally, multiple procedures are needed to create a permanent venous access. Therefore, there is a growing global interest in urgently initiated peritoneal dialysis (PD), with several clinical studies attesting to its safety, efficacy, and feasibility. However, little has been known about early PD complications and the long-term prognosis of patients in terms of technical and infectious complications.
Source: Chronic Kidney Disease 8. 6. 2021

News Metamizole in the Treatment of Acute Postoperative Pain

In many countries, metamizole is considered a first-choice non-opioid analgesic. The analysis presented below, published in the Cochrane Database of Systematic Reviews, examined the efficacy and safety of metamizole in the treatment of acute postoperative pain.
Source: Analgesia 25. 5. 2021

News Case of Heparin Allergy and Preventive Administration of Fondaparinux in Pregnancy –⁠ Case Study

The presented case study discusses a complicated case of a 40-year-old woman with essential thrombocythemia (ET), a history of intrauterine fetal death, and recurrent pulmonary embolism (PE). The patient developed an allergic reaction to low-molecular-weight heparin (LMWH) and was successfully managed with fondaparinux during pregnancy.
Source: Management of Thrombosis in Women 20. 5. 2021

News INFOGRAPHIC: Prevention and Management of Hypotension During Sacubitril/Valsartan Treatment

Despite the undeniable benefits of sacubitril/valsartan in terms of morbidity and mortality in patients with chronic heart failure, its administration can be complicated by side effects. The most common of these is hypotension.
Source: Chronic Heart Failure and Lipidology 20. 5. 2021

News Thrombocytopenia Following mRNA Vaccination Against SARS-CoV-2

In connection with the administration of mRNA-based vaccines against the SARS-CoV-2 coronavirus, cases of secondary immune thrombocytopenia (ITP) have been described. A commentary published by a large team of authors in the American Journal of Hematology described a series of cases of low platelet counts identified within 2 weeks of vaccination. The data was obtained from the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Department of Health and Human Services (HHS), and the Vaccine Adverse Event Reporting System (VAERS), as well as through direct communication with patients and their physicians.
Source: Immune Thrombocytopenia 20. 5. 2021

News Options for Reducing or Discontinuing TPO-RA Therapy in ITP Patients −⁠ Expert Consensus

There are currently no clear recommendations regarding dose reduction or discontinuation of thrombopoietin receptor agonists (TPO-RA) in patients with immune thrombocytopenia (ITP). A consensus by British authors offers insights into current clinical practice and the related issues.
Source: Immune Thrombocytopenia 20. 5. 2021

News Quality of Life of Hemophiliacs and Ways to Improve It

Determining the quality of life (QoL) also reflects the morbidity associated with the disease, in this case, hemophilia. In the study presented below, the authors focused on determining QoL in relation to socioeconomic and other characteristics.
Source: Hemophilia with Movement 21. 5. 2021

1 32 33 34 35 36 667
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#